Taysha Gene Therapies, Inc. (TSHA)
6.04
+0.02
(+0.33%)
USD |
NASDAQ |
Aug 27, 14:39
Taysha Gene Therapies Price to Book Value : 5.074 for Aug. 27, 2026
Price to Book Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Price to Book Value Data
| Date | Value |
|---|---|
| August 26, 2026 | 5.057 |
| August 25, 2026 | 5.208 |
| August 24, 2026 | 5.015 |
| August 21, 2026 | 5.116 |
| August 20, 2026 | 5.132 |
| August 19, 2026 | 5.401 |
| August 18, 2026 | 5.200 |
| August 17, 2026 | 5.216 |
| August 14, 2026 | 4.998 |
| August 13, 2026 | 5.032 |
| August 12, 2026 | 5.380 |
| August 11, 2026 | 5.611 |
| August 10, 2026 | 5.351 |
| August 07, 2026 | 5.510 |
| August 06, 2026 | 5.326 |
| August 05, 2026 | 5.426 |
| August 04, 2026 | 5.208 |
| August 03, 2026 | 4.855 |
| July 31, 2026 | 4.922 |
| July 30, 2026 | 4.935 |
| July 29, 2026 | 4.712 |
| July 28, 2026 | 4.586 |
| July 27, 2026 | 4.654 |
| July 24, 2026 | 4.637 |
| July 23, 2026 | 4.897 |
| Date | Value |
|---|---|
| July 22, 2026 | 4.754 |
| July 21, 2026 | 4.763 |
| July 20, 2026 | 4.687 |
| July 17, 2026 | 5.006 |
| July 16, 2026 | 5.015 |
| July 15, 2026 | 5.200 |
| July 14, 2026 | 4.788 |
| July 13, 2026 | 4.519 |
| July 10, 2026 | 5.326 |
| July 09, 2026 | 5.519 |
| July 08, 2026 | 5.452 |
| July 07, 2026 | 5.46 |
| July 06, 2026 | 5.359 |
| July 02, 2026 | 5.485 |
| July 01, 2026 | 5.586 |
| June 30, 2026 | 5.720 |
| June 29, 2026 | 9.122 |
| June 26, 2026 | 8.594 |
| June 25, 2026 | 8.417 |
| June 24, 2026 | 9.407 |
| June 23, 2026 | 9.298 |
| June 22, 2026 | 8.851 |
| June 18, 2026 | 8.702 |
| June 17, 2026 | 8.390 |
| June 16, 2026 | 7.929 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Price to Book Value Benchmarks
| Altimmune, Inc. | 1.310 |
| Protalix Biotherapeutics, Inc. | 2.923 |
| Humacyte, Inc. | 6.237 |
| Agenus, Inc. | -- |
| Amgen, Inc. | 20.25 |
Price to Book Value Related Metrics
| PS Ratio | 378.27 |
| PEG Ratio | -0.6624 |
| Price | 6.04 |
| Earnings Yield | -7.16% |
| Market Cap | 1.965B |
| PEGY Ratio | -0.6624 |